New combo therapy aims to control tough lymphoma
NCT ID NCT02446236
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in adults with mantle cell lymphoma that has come back or not responded to prior treatment. The main goal is to find the safest dose by monitoring side effects. Up to 27 participants will receive the drugs until their disease worsens or side effects become unacceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.